Objective To observe the efficacy of ticagrelor on patients with clopidogrel resistance after emergency percutaneous coronary intervention (PCI) .Methods Eight-five patients with clopidogrel resistance after PCI were divided into groups of A (treated with ticagrelor 90 mg , twice per day ,41 cases) and B(treated with clopidogrel 75 mg per day ,44 cases) .Platelet aggregation rate ,adverse effects and major adverse cardiac event (MACE) in one week ,one month and three months after PCI were observed and compared between two groups .Results Platelet aggregation rates during treatment of one week to three months were lower in group A than those in group B (P<0 .05) .Blood uric acid level in one week after PCI in group A was higher than that in group B (P<0 .05) .There were no significant differences between two groups in the rates of dyspnea and bleeding events(P>0 .05) .But the incidence of MACE in three months was lower in group A than that in group B(P<0 .05) .Conclusion Ticagrelor orally taken can improve the prognosis of patients with clopidogrel resistance after emergency PCI ,but attention should be paid to the occurrence of adverse effects during ticagrelor treatment .%目的 观察替格瑞洛治疗急诊经皮冠脉介入治疗(PCI)术后氯吡格雷抵抗的疗效.方法 85例急性心肌梗死行急诊PCI治疗且术后发生氯吡格雷抵抗患者分别口服替格瑞洛90 mg每日2次(A组 ,41例)和氯吡格雷75 m g/d (B组 ,44例)治疗.观察两组患者服药后1周及1、3个月血小板聚集率、不良反应和主要不良心脏事件(MACE)发生情况.结果 A组治疗期间血小板聚集率均低于B组(P<0 .05).A组术后1周血尿酸水平高于B组(P<0 .05).两组患者呼吸困难和出血事件发生率比较无统计学差异( P>0 .05 ) ,但是术后 3 个月 A 组总 M ACE 发生率低于 B组(P<0 .05).结论 急诊PCI术后氯吡格雷抵抗患者口服替格瑞洛可改善预后 ,但仍需警惕不良反应的发生.
展开▼
